An experimental antiviral drug can significantly decrease levels of the virus causing COVID-19 and the damage it causes in the lungs, according to new research.
One in three survivors of COVID-19, those more commonly referred to as COVID-19 long-haulers, suffered from neurologic or psychiatric disability six months after infection, a recent […]